The American Journal of Managed Care13h
Tildrakizumab Effectively Enhances Quality of Life in Moderate to Severe Psoriasis
Study highlights the efficacy and safety of tildrakizumab in improving physical, psychological, and social aspects of quality ...
Malaysian Reserve7h
Incyte and Syndax Announce U.S. Food and Drug Administration (FDA) Approval of Niktimvo™ (axatilimab-csfr) 9 mg and 22 mg Vial Sizes
Incyte (Nasdaq:INCY) and Syndax Pharmaceuticals (Nasdaq:SNDX) today announced that the U.S. Food and Drug Admin ...
Le Lézard7h
Incyte and Syndax Announce U.S. Food and Drug Administration (FDA) Approval of Niktimvotm (axatilimab-csfr) 9 mg and 22 mg Vial Sizes
Niktimvo (axatilimab-csfr) is a first-in-class colony stimulating factor-1 receptor (CSF-1R)-blocking antibody approved for use in the U.S. for the treatment of chronic graft-versus-host disease (GVHD ...